These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26549908)

  • 1. Access to hepatitis C medicines.
    Edwards DJ; Coppens DG; Prasad TL; Rook LA; Iyer JK
    Bull World Health Organ; 2015 Nov; 93(11):799-805. PubMed ID: 26549908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.
    Grillon C; Krishtel PR; Mellouk O; Basenko A; Freeman J; Mendão L; Andrieux-Meyer I; Morin S
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25060. PubMed ID: 29633580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis.
    Simmons B; Cooke GS; Miraldo M
    Lancet Glob Health; 2019 Sep; 7(9):e1189-e1196. PubMed ID: 31362914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A path to eradication of hepatitis C in low- and middle-income countries.
    Graham CS; Swan T
    Antiviral Res; 2015 Jul; 119():89-96. PubMed ID: 25615583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
    James JS
    AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal Medicine Access through Lump-Sum Remuneration - Australia's Approach to Hepatitis C.
    Moon S; Erickson E
    N Engl J Med; 2019 Feb; 380(7):607-610. PubMed ID: 30763190
    [No Abstract]   [Full Text] [Related]  

  • 8. Access to HCV treatments: hurdles not barriers.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):1. PubMed ID: 28404005
    [No Abstract]   [Full Text] [Related]  

  • 9. Role Of Generics In Treatment Of Hepatitis C Infection.
    Umar M; Akhter TS; Akbar I; Nisar G; Osama M; Akhter TS
    J Ayub Med Coll Abbottabad; 2016; 28(4 Suppl 1):S890-S894. PubMed ID: 28782339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.
    Gaayeb L; Das A; James I; Murthy R; Nobre S; Burrone E; Morin S
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26092. PubMed ID: 37439078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to essential medicines for sexual and reproductive health care: the role of the pharmaceutical industry and international regulation.
    Cottingham J; Berer M
    Reprod Health Matters; 2011 Nov; 19(38):69-84. PubMed ID: 22118143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Companies reduce prices for HIV drugs in developing countries.
    Gottlieb S
    Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C eradication: A long way to go.
    Waheed Y
    World J Gastroenterol; 2015 Nov; 21(43):12510-2. PubMed ID: 26604658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmaceutical industry as a medicines provider.
    Henry D; Lexchin J
    Lancet; 2002 Nov; 360(9345):1590-5. PubMed ID: 12443614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to improve access to therapy in hepatitis B patients.
    Subic M; Zoulim F
    Liver Int; 2018 Feb; 38 Suppl 1():115-121. PubMed ID: 29427482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence.
    Rockers PC; Wirtz VJ; Umeh CA; Swamy PM; Laing RO
    Health Aff (Millwood); 2017 Apr; 36(4):706-713. PubMed ID: 28373337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public procurement of hepatitis C medicines in Brazil from 2005 to 2015.
    Chaves GC; Castro CGSO; Oliveira MA
    Cien Saude Colet; 2017 Aug; 22(8):2527-2538. PubMed ID: 28793069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C drugs not reaching poor.
    Callaway E
    Nature; 2014 Apr; 508(7496):295-6. PubMed ID: 24740042
    [No Abstract]   [Full Text] [Related]  

  • 19. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
    Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia?
    Tenni B; Lexchin J; Phin S; Gleeson D
    Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):295-308. PubMed ID: 38563076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.